Pharmaniaga

PHARMA

MYL7081OO002

Pharmaceuticals

End-of-day quote BURSA MALAYSIA Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
0.355 ^MYR	+10.94%		+14.52%	-7.79%

19/04	China's drugmakers can't sell mRNA shots but haven't quit yet	RE
27/03	Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee	CI

Pharmaniaga Berhad Not to Announce Dividend for the Fourth Quarter of Financial Year Ended 31 December 2022

February 27, 2023 at 06:06 pm IST

Pharmaniaga Berhad announced that no fourth interim dividend (2021: 5.0 sen) was proposed or declared in respect of the financial year ended 31 December 2022 (2021: MYR 65.5 million).

Latest news about Pharmaniaga

China's drugmakers can't sell mRNA shots but haven't quit yet	19/04	RE
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee	27/03	CI
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Nomination and Remuneration Committee	27/03	CI
Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof as Independent and Non Executive Member of Risk Committee	27/03	CI
Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof as Independent and Non Executive Member of Nomination and Remuneration Committee	27/03	CI
Pharmaniaga Berhad Appoints Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Chairman of Risk Committee	27/03	CI
Pharmaniaga Berhad Announces Redesignation of Puan Sarah Azreen Binti Abdul Samat from Chairman of Risk Committee to Member of Risk Committee	27/03	CI
Pharmaniaga Berhad Appoints Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Member of Audit Committee	27/03	CI
Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer	08/03	CI
Pharmaniaga Trims Loss in Q4 2024	04/03	MT
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024	29/02	CI
Pharmaniaga Berhad Appoints Encik Zulkifli Bin Jafar as Executive Director, Effective March 1, 2024	29/02	CI
Pharmaniaga Berhad Appoints Dato Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Director, Effective from March 1, 2024	29/02	CI
Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024	29/02	CI
Pharmaniaga Berhad Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director	19/02	CI
Pharmaniaga, Malaysia's Health Ministry Sign Seven-Year Consession Deal	05/01	MT
Pharmaniaga Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
Bourse Denies Pharmaniaga's Private Placement Appeal	18/23/18	MT
Pharmaniaga Logs Higher Profit, Revenue in Q2	14/23/14	MT
Pharmaniaga Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Pharmaniaga Berhad Announces Re-Designation of Puan Sarah Azreen Abdul Samat from Member of Risk Committee to Chairman of Risk Committee	10/23/10	CI
Pharmaniaga Berhad Announces Appointment of Encik Ahmad Shahredzuan Mohd Shariff as Non Independent and Non Executive Member of Risk Committee	10/23/10	CI
Pharmaniaga Berhad Appoints Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director	10/23/10	CI
Pharmaniaga Berhad Appoints Encik Mohammad Ashraf Bin Md. Radzi as Non Independent and Non Executive Director	10/23/10	CI

Pharmaniaga Berhad is an investment holding company. The Company is principally engaged in the research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales, and marketing, as well as community pharmacy. The Company operates through three segments: Logistics and distribution, Manufacturing, and Indonesia. The Logistics and distribution is engaged in the distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Manufacturing segment is engaged in the manufacturing of pharmaceutical products in Malaysia. Indonesia segment is engaged in the manufacturing and distribution of pharmaceutical and medical products in Indonesia. The Companyâs subsidiaries include Idaman Pharma Manufacturing Sdn. Bhd., Pharmaniaga Manufacturing Berhad, Pharmaniaga LifeScience Sdn. Bhd., Pharmaniaga Logistics Sdn. Bhd., and Pharmaniaga Marketing Sdn. Bhd.

Sector

Pharmaceuticals

Calendar

05/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Pharmaniaga

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.355 MYR

Average target price

0.31 MYR

Spread / Average Target

-12.68%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
PHARMANIAGA	-7.79%	9.83Cr
MCKESSON CORPORATION	+20.86%	7.25TCr
CARDINAL HEALTH, INC.	-4.50%	2.35TCr
SINOPHARM GROUP CO. LTD.	+4.89%	859.45Cr
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+7.11%	835.21Cr
HUADONG MEDICINE CO., LTD	-23.73%	788.23Cr
H. LUNDBECK A/S	+13.92%	521.3Cr
EBOS GROUP LIMITED	-0.59%	410.54Cr
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+7.85%	408.6Cr
CHINA NATIONAL MEDICINES CORPORATION LTD.	+20.65%	360.03Cr

Pharmaceuticals Wholesale

Pharmaniaga

Equities

PHARMA

MYL7081OO002

Pharmaceuticals

Pharmaniaga Berhad Not to Announce Dividend for the Fourth Quarter of Financial Year Ended 31 December 2022

Latest news about Pharmaniaga

Chart Pharmaniaga

Company Profile

Income Statement Evolution

Ratings for Pharmaniaga

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Pharmaceuticals Wholesale